Phoenix, United States
VisionGate, Inc. is a pioneering liquid-biopsy technology company focused on combatting lung cancer through early detection technology with a non-intrusive sputum test. Their proprietary Cell-CT™ 3-Dimensional Cell Imaging and Analysis platform forms the basis of their diagnostic capabilities, utilizing optical computed tomography to create 3D images of individual cells and recognize over 700 structural biomarkers. This platform has broad potential applicability across different cancers and biosignatures, promising potential aid in identifying targeted pharmaceutical therapies.
Their flagship product, the LuCED® lung test, is a non-invasive sputum-based test designed to detect abnormal cells indicating lung cancer and bronchial dysplasia. Leveraging the Cell-CT platform, it is being developed for early lung cancer detection, bronchial dysplasia, and the assessment of indeterminate pulmonary nodules. Additionally, the LuCED test features the CellGazer™ application, an imaging software tool aimed at facilitating cytopathology diagnosis of abnormal cell images detected by the Cell-CT platform.
Founded in 2001 and headquartered in the United States, VisionGate, Inc. secured a notable $36.56M Venture Round investment on 23 December 2019. This investment highlights the confidence of investors in the potential of VisionGate's innovative technology to revolutionize the early detection and diagnosis of lung cancer, underscoring the company’s significance within the Biotechnology and Health Care industries. For more information, visit www.visiongate3d.com.
